WallStSmart

Cytek Biosciences Inc (CTKB)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 17711% more annual revenue ($36.36B vs $204.17M). MDT leads profitability with a 13.2% profit margin vs -36.2%. MDT earns a higher WallStSmart Score of 62/100 (C+).

CTKB

Hold

41

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 6.7Quality: 8.5
Piotroski: 4/9Altman Z: 2.45

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CTKBUndervalued (+41.3%)

Margin of Safety

+41.3%

Fair Value

$7.43

Current Price

$4.31

$3.12 discount

UndervaluedFair: $7.43Overvalued
MDTUndervalued (+10.6%)

Margin of Safety

+10.6%

Fair Value

$91.75

Current Price

$87.54

$4.21 discount

UndervaluedFair: $91.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTKB3 strengths · Avg: 9.0/10
EPS GrowthGrowth
73.5%10/10

Earnings expanding 73.5% YoY

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$106.61B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

CTKB4 concerns · Avg: 2.0/10
Market CapQuality
$588.89M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-22.6%2/10

ROE of -22.6% — below average capital efficiency

Free Cash FlowQuality
$-4.90M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-36.2%1/10

Currently unprofitable

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CTKB

The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : CTKB

The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

CTKB profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

CTKB carries more volatility with a beta of 1.17 — expect wider price swings.

MDT is growing revenue faster at 9.9% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 41/100). CTKB offers better value entry with a 41.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cytek Biosciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer diagnostics, and drug development. The company leverages its proprietary technologies to meet the growing demand for precision in cellular analytics, positioning itself as a key player in the biotechnology sector. With a robust product portfolio and a commitment to exceptional customer support, Cytek is well-equipped to drive transformative discoveries, ultimately enhancing healthcare outcomes and addressing critical challenges in the life sciences.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?